239 related articles for article (PubMed ID: 30872117)
1. Immunodeficiency and EBV-induced lymphoproliferation caused by 4-1BB deficiency.
Alosaimi MF; Hoenig M; Jaber F; Platt CD; Jones J; Wallace J; Debatin KM; Schulz A; Jacobsen E; Möller P; Shamseldin HE; Abdulwahab F; Ibrahim N; Alardati H; Almuhizi F; Abosoudah IF; Basha TA; Chou J; Alkuraya FS; Geha RS
J Allergy Clin Immunol; 2019 Aug; 144(2):574-583.e5. PubMed ID: 30872117
[TBL] [Abstract][Full Text] [Related]
2. Concomitant
Rodriguez R; Fournier B; Cordeiro DJ; Winter S; Izawa K; Martin E; Boutboul D; Lenoir C; Fraitag S; Kracker S; Watts TH; Picard C; Bruneau J; Callebaut I; Fischer A; Neven B; Latour S
J Exp Med; 2019 Dec; 216(12):2800-2818. PubMed ID: 31537641
[TBL] [Abstract][Full Text] [Related]
3. Gene-corrected human Munc13-4-deficient CD8+ T cells can efficiently restrict EBV-driven lymphoproliferation in immunodeficient mice.
Soheili T; Rivière J; Ricciardelli I; Durand A; Verhoeyen E; Derrien AC; Lagresle-Peyrou C; de Saint Basile G; Cosset FL; Amrolia P; André-Schmutz I; Cavazzana M
Blood; 2016 Dec; 128(24):2859-2862. PubMed ID: 27799161
[No Abstract] [Full Text] [Related]
4. Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP.
Palendira U; Low C; Chan A; Hislop AD; Ho E; Phan TG; Deenick E; Cook MC; Riminton DS; Choo S; Loh R; Alvaro F; Booth C; Gaspar HB; Moretta A; Khanna R; Rickinson AB; Tangye SG
PLoS Biol; 2011 Nov; 9(11):e1001187. PubMed ID: 22069374
[TBL] [Abstract][Full Text] [Related]
5. Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27.
Salzer E; Daschkey S; Choo S; Gombert M; Santos-Valente E; Ginzel S; Schwendinger M; Haas OA; Fritsch G; Pickl WF; Förster-Waldl E; Borkhardt A; Boztug K; Bienemann K; Seidel MG
Haematologica; 2013 Mar; 98(3):473-8. PubMed ID: 22801960
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus-specific T-cell cytotoxicity is mediated through the perforin pathway in patients with lymphoproliferative disorders after allogeneic bone marrow transplantation.
Yoshimi A; Tsuge I; Namizaki H; Hoshino Y; Kimura H; Takahashi Y; Watanabe N; Kuzushima K; Kojima S
Br J Haematol; 2002 Mar; 116(3):710-5. PubMed ID: 11849237
[TBL] [Abstract][Full Text] [Related]
7. Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity.
Edwards ESJ; Bier J; Cole TS; Wong M; Hsu P; Berglund LJ; Boztug K; Lau A; Gostick E; Price DA; O'Sullivan M; Meyts I; Choo S; Gray P; Holland SM; Deenick EK; Uzel G; Tangye SG
J Allergy Clin Immunol; 2019 Jan; 143(1):276-291.e6. PubMed ID: 29800648
[TBL] [Abstract][Full Text] [Related]
8. Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases.
Latour S; Fischer A
Immunol Rev; 2019 Sep; 291(1):174-189. PubMed ID: 31402499
[TBL] [Abstract][Full Text] [Related]
9. Successful hematopoietic stem cell transplantation in a 4-1BB deficient patient with EBV-induced lymphoproliferation.
Wildermann C; Alosaimi M; Liebenehm S; Jacobsen EM; Barth TFE; Möller P; Debatin KM; Schulz A; Sirin M; Abosoudah IF; Alkuraya FS; Geha RS; Hönig M
Clin Immunol; 2021 Jan; 222():108639. PubMed ID: 33259966
[TBL] [Abstract][Full Text] [Related]
10. Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency.
Abolhassani H; Edwards ES; Ikinciogullari A; Jing H; Borte S; Buggert M; Du L; Matsuda-Lennikov M; Romano R; Caridha R; Bade S; Zhang Y; Frederiksen J; Fang M; Bal SK; Haskologlu S; Dogu F; Tacyildiz N; Matthews HF; McElwee JJ; Gostick E; Price DA; Palendira U; Aghamohammadi A; Boisson B; Rezaei N; Karlsson AC; Lenardo MJ; Casanova JL; Hammarström L; Tangye SG; Su HC; Pan-Hammarström Q
J Exp Med; 2017 Jan; 214(1):91-106. PubMed ID: 28011864
[TBL] [Abstract][Full Text] [Related]
11. Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets.
Hislop AD; Palendira U; Leese AM; Arkwright PD; Rohrlich PS; Tangye SG; Gaspar HB; Lankester AC; Moretta A; Rickinson AB
Blood; 2010 Oct; 116(17):3249-57. PubMed ID: 20644117
[TBL] [Abstract][Full Text] [Related]
12. Nodal EBV-positive polymorphic B cell lymphoproliferative disorder with plasma cell differentiation: clinicopathological analysis of five cases.
Satou A; Tabata T; Suzuki Y; Sato Y; Tahara I; Mochizuki K; Oishi N; Takahara T; Yoshino T; Tsuzuki T; Nakamura S
Virchows Arch; 2021 May; 478(5):969-976. PubMed ID: 33169195
[TBL] [Abstract][Full Text] [Related]
13. Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice.
Wagar EJ; Cromwell MA; Shultz LD; Woda BA; Sullivan JL; Hesselton RM; Greiner DL
J Immunol; 2000 Jul; 165(1):518-27. PubMed ID: 10861091
[TBL] [Abstract][Full Text] [Related]
14. CD27 is required for protective lytic EBV antigen-specific CD8+ T-cell expansion.
Deng Y; Chatterjee B; Zens K; Zdimerova H; Müller A; Schuhmachers P; Ligeon LA; Bongiovanni A; Capaul R; Zbinden A; Holler A; Stauss H; Hammerschmidt W; Münz C
Blood; 2021 Jun; 137(23):3225-3236. PubMed ID: 33827115
[TBL] [Abstract][Full Text] [Related]
15. Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation.
Huck K; Feyen O; Niehues T; Rüschendorf F; Hübner N; Laws HJ; Telieps T; Knapp S; Wacker HH; Meindl A; Jumaa H; Borkhardt A
J Clin Invest; 2009 May; 119(5):1350-8. PubMed ID: 19425169
[TBL] [Abstract][Full Text] [Related]
16. The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease.
Patton JT; Lustberg ME; Lozanski G; Garman SL; Towns WH; Drohan CM; Lehman A; Zhang X; Bolon B; Pan L; Kinghorn AD; Grever MR; Lucas DM; Baiocchi RA
Oncotarget; 2015 Feb; 6(5):2693-708. PubMed ID: 25393910
[TBL] [Abstract][Full Text] [Related]
17. Long-term carriers generate Epstein-Barr virus (EBV)-specific CD4(+) and CD8(+) polyfunctional T-cell responses which show immunodominance hierarchies of EBV proteins.
Ning RJ; Xu XQ; Chan KH; Chiang AK
Immunology; 2011 Oct; 134(2):161-71. PubMed ID: 21896011
[TBL] [Abstract][Full Text] [Related]
18. Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors.
Eom HS; Choi BK; Lee Y; Lee H; Yun T; Kim YH; Lee JJ; Kwon BS
J Immunother; 2016 Apr; 39(3):140-8. PubMed ID: 26938947
[TBL] [Abstract][Full Text] [Related]
19. Dysregulation of Epstein-Barr Virus Infection in Hypomorphic ZAP70 Mutation.
Hoshino A; Takashima T; Yoshida K; Morimoto A; Kawahara Y; Yeh TW; Okano T; Yamashita M; Mitsuiki N; Imai K; Sakatani T; Nakazawa A; Okuno Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Ogawa S; Kojima S; Morio T; Kanegane H
J Infect Dis; 2018 Jul; 218(5):825-834. PubMed ID: 29684201
[TBL] [Abstract][Full Text] [Related]
20. Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4
Choi IK; Wang Z; Ke Q; Hong M; Qian Y; Zhao X; Liu Y; Kim HJ; Ritz J; Cantor H; Rajewsky K; Wucherpfennig KW; Zhang B
Proc Natl Acad Sci U S A; 2018 Jan; 115(4):E686-E695. PubMed ID: 29311309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
